A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development

CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete Tstem, affecting clinical outcome. YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validated C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer discovery 2023-09, Vol.13 (9), p.1982-1997
Hauptverfasser: Dickinson, Michael J, Barba, Pere, Jager, Ulrich, Shah, Nirav N, Blaise, Didier, Briones, Javier, Shune, Leyla, Boissel, Nicolas, Bondanza, Attilio, Mariconti, Luisa, Marchal, Anne-Laure, Quinn, David S, Yang, Jennifer, Price, Andrew, Sohoni, Akash, Treanor, Louise M, Orlando, Elena J, Mataraza, Jennifer, Davis, Jaclyn, Lu, Darlene, Zhu, Xu, Engels, Boris, Moutouh-de Parseval, Laure, Brogdon, Jennifer L, Moschetta, Michele, Flinn, Ian W
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete Tstem, affecting clinical outcome. YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validated CAR as tisagenlecleucel, is manufactured using a next-generation platform in
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-22-1276